Neuren Pharmaceuticals Limited (OTCMKTS:NURPF – Get Free Report) rose 10.1% during mid-day trading on Friday . The company traded as high as C$12.91 and last traded at C$12.91. Approximately 190 shares were traded during trading, a decline of 84% from the average daily volume of 1,169 shares. The stock had previously closed at C$11.73.
Neuren Pharmaceuticals Stock Performance
The stock’s 50 day moving average price is C$13.03 and its 200-day moving average price is C$10.63.
About Neuren Pharmaceuticals
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome.
Recommended Stories
- Five stocks we like better than Neuren Pharmaceuticals
- How to Most Effectively Use the MarketBeat Earnings Screener
- AI Demand Is Coming—Is Microchip Technology Ready?
- Want to Profit on the Downtrend? Downtrends, Explained.
- Why Investors Have Flocked to 2 Unorthodox ETFs This Month
- When to Sell a Stock for Profit or Loss
- Rivian’s Chart Says Go, But Some Analysts Still Say No
Receive News & Ratings for Neuren Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuren Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
